December 2016
-
CDMO MedPharm announced that it has added human epithelial cell models for screening of drugs intended for the treatment of coronaviruses at its facility in Durham, North Carolina, US. The company says that use of… Read more . . .
-
Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG’s “Emergency Call to research COVID-19… Read more . . .
-
According to Zambon, the FDA has granted Fast Track designation to the company’s liposomal cyclosporine A for inhalation (L‑CsA‑i), which is in Phase 3 development for the treatment of bronchiolitis obliterans syndrome (BOS). Zambon acquired… Read more . . .
-
Avalyn Pharma (formerly Genoa Pharmaceuticals) announced that it has raised $35.5 million in a Series B financing round led by Norwest Venture Partners. The proceeds will fund a Phase 2/3 trial Avalyn’s AP01 nebulized pirfenidone… Read more . . .
-
Digital RDD 2020 got underway on April 26 with the announcement of the winner of the Charles G. Thiel Award for Outstanding Research and Discovery in Respiratory Drug Delivery. In a recorded presentation accessible to… Read more . . .
-
Inhalation Sciences (ISAB) announced that it has sold all of its remaining shares in its spinoff Ziccum AB, a spray drying specialist, for a total of approximately SEK 21.2 million. In May 2019, ISAB announced that… Read more . . .
-
Less than two weeks after announcing the promotion of Mike Motion from Chief Commercial Officer to Chief Operating Officer, inhaler monitoring company Adherium has named Motion as its new CEO, replacing interim CEO Jeremy Curnock… Read more . . .
-
Alpha Cognition Inc. (formerly Neurodyn Cognition) and CRO Linical have announced Linical will provide consulting services related to potential development of Alpha Cognition’s Alpha-1062 acetyl choline esterase inhibitor (AChEI) for the treatment of Alzheimer’s disease.… Read more . . .
-
Biomarck Pharmaceuticals said that a Phase 2a clinical trial of its BIO-11006 inhalation solution in patients with acute respiratory distress syndrome (ARDS) met its primary endpoint, with a 43% decrease in mortality at 28 days… Read more . . .
-
Theravance Biopharma said that a Phase 1 study of its TD-0903 nebulized JAK inhibitor is now underway. Earlier this month, Theravance announced that it intended to begin clinical development of TD-0903 for the prevention of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland